Breaking News

AstraZeneca to Invest in Shanghai Innovation Center

Will establish a commercial cell therapy manufacturing and supply base, enabling end-to-end cell therapy capabilities in China.

Author Image

By: Charlie Sternberg

Associate Editor

AstraZeneca has announced plans to establish a commercial cell therapy manufacturing and supply base and innovation center in Shanghai, enabling end-to-end cell therapy capabilities in China.

The company will build the dedicated commercial cell therapy manufacturing and supply base in the Lingang New Area of ​​the Shanghai Free Trade Zone for the commercial production and supply of autologous CAR-T cell therapies in China and other Asian markets, including AZD0120, a BCMA/CD19 dual-target CAR-T cell therapy, which is currently undergoing clinical trials in the fields of multiple myeloma and autoimmune diseases.

The company will also establish the AstraZeneca Gracell Cell Therapy Innovation Center in Shanghai Zhangjiang High-Tech Park, covering early-stage research, viral vector and plasmid development, analytical testing, clinical manufacturing, and registration support.

More AstraZeneca News

Last year, AstraZeneca announced a $50 billion investment in the United States.

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters